Phase 2 N=41 PH94B in the Treatment of Adjustment Disorder With Anxiety
Adjustment Disorder With Anxious Mood
Primary: Hamilton Anxiety Scale (HAM-A) Score — -12.5; -12.6 score on a scale — p=0.9338
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=495 EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder (GAD)
Primary: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42) — -9.01; -8.93 Score on scale
N/A N=918 Expectation of Unpleasant Events in Anxiety Disorders
Anxiety Disorders
Primary: Change in Percent of Correct Button Presses During Threat Compared to the Safe Condition (AAST) — -0.016; 0.008 Percentage of accurate responses
Phase 2 N=160 An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
Depressive Disorder · Anxiety
Primary: Double-blind Treatment Period: Change From Baseline in Hamilton Depression Rating Scale (HDRS17) Total Score at Week 6 (eITT Population) — -6.1; -6.5 Units on a scale…
N/A N=37 A Unified Treatment for Anxiety Disorders
Emotional Disorders · Anxiety Disorders
Primary: Anxiety Disorders Interview Schedule for DSM-IV — 5.23; 5.09; 3.18; 5.14 score on a scale
Phase 4 N=418 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Generalized Anxiety Disorder · Panic Disorder
Primary: Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat…
Phase 2 N=83 SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Generalized Anxiety Disorder (GAD) · Anxiety, Separation · Phobia, Social
Primary: Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks — -1.7; -2.3 mmHg
N/A N=31 Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism
Autism · Asperger's Syndrome · Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale — 10.94; 13.93 units on a scale
Phase 3 N=210 Duloxetine for the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint — 12.76; 13.56; -6.38; -5.29 Units on a scale — p=0.006
Phase 3 N=281 A Study in Pediatric Participants With Generalized Anxiety Disorder
Anxiety Neuroses · Anxiety States, Neurotic · Neuroses, Anxiety
Primary: Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety…
N/A N=53 Attention Bias Modification Training in Youth With Subthreshold Impairing Anxiety
Anxiety
Primary: Pediatric Anxiety Rating Scale at Posttreatment — 7.21; 7.73 units on a scale
N/A N=21 Neurally Targeted Cognitive Training to Augment CBT Outcomes in Pediatric Anxiety
Anxiety Disorders
Primary: Change in Brain Activation and Connectivity in the Task-control Network (TCN) — 0.020; -0.206; 0.305; -0.004 Arbitrary Units
Phase 3 N=45 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
Autism · Asperger's Syndrome · Generalized Anxiety Disorder
Primary: Pediatric Anxiety Rating Scale (Measures the Severity of Anxiety Symptoms) — 16.33; 17.62; 11.58; 16.05 units on a scale
Phase 4 N=1,004 Primary Care Intervention Strategy for Anxiety Disorders
Post-traumatic Stress Disorder · Generalized Anxiety Disorder · Panic Disorder
Primary: BSI-12 (Anxiety and Somatization Subscales) — 325; 258 number of responders
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Phase 3 N=30 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Autism Spectrum Disorders
Primary: Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase — -4.9; -3.2 score on a scale
N/A N=56 Anxiety in Older Veterans
Anxiety Disorders
Primary: Change in Anxiety Symptoms — 1.77; -2.42 units on a scale
N/A N=167 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
Autism Spectrum Disorders · Autism · Asperger's Syndrome
Primary: Change From Baseline in Anxiety Severity on the Pediatric Anxiety Rating Scale After 16 Weeks of Treatment. — 3.43; 3.47; 3.28; 2.13 units on a scale
Phase 4 N=90 Acamprosate in Alcoholics With Comorbid Anxiety or Depression
Alcohol Dependence · Major Depression · Social Anxiety Disorder
Primary: Percent Days Drinking — 34.9; 31.9 percentage of days drinking — p=0.64
Phase 3 N=511 Experimental Medication For the Treatment of Generalized Anxiety Disorder
Anxiety Disorder
Primary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540
N/A N=32 Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety
Autism · Asperger's Syndrome · Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale — 7.79; 15.06 units on a scale
N/A N=50 Threat Interpretation Bias as Cognitive Marker and Treatment Target in Pediatric Anxiety
Anxiety Disorders
Primary: Change in Linguistic Interpretation Bias as Assessed by the Word-sentence Association Paradigm for Youth (WSAP-Y) — 19.77; 47.40 score on a scale
Phase 3 N=265 Transdiagnostic Cognitive Behavioral Treatment for Anxiety
Anxiety Disorders
Primary: CRIS-EPS: Comparison of Extent of Participation Scores Among iCBT, sCBT, and TAU Groups From Baseline to 1, 3, and 6 Month Follow Ups — 4.21; 4.18; 4.17; 4.52 score on a…
Phase 4 N=25 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)
Generalized Anxiety Disorder
Primary: Change in Hamilton Anxiety Rating Scale Score — -6.4 units on a scale
Phase 2 N=33 Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale. — 11.62; 14.04 units on a scale — p=.04
Phase 3 N=488 Child and Adolescent Anxiety Disorders (CAMS)
Anxiety Disorders · Social Phobia · Generalized Anxiety Disorder
Primary: Clinical Global Impression - Improvement Scale — 54.9; 59.7; 80.7; 23.7 percentage of participants
Phase 3 N=37 Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
Major Depressive Disorder · Anxiety
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -19.6 Units on a scale — p=<0.0001
N/A N=76 A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: High End State Function — 56.52; 43.48; 56.52; 47.62 % people meeting high endstate status
Phase 3 N=409 Generalized Anxiety Disorder Adjunct Study
Anxiety · Anxiety Disorders · Anxiety Neuroses
Primary: Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.74; -9.61 units on scale
N/A N=35 Reducing Anxiety and Stress in Primary Care Patients
Anxiety
Primary: Generalized Anxiety Disorder-7 at Post-Assessment — 12.5; 12.0; 4.6; 9.1 score on a scale — p=0.035